MoonLake Immunotherapeutics(MLTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MLTX MoonLake Immunotherapeutics

Not Yet Opened 04-08 16:00:00 EDT

18.60

+1.52

+8.90%

盘后18.50

-0.10-0.54%

19:56 EDT

High18.78	Low17.10	Vol1.84M
Open17.38	D1 Closing17.08	Amplitude9.83%
Mkt Cap1.33B	Tradable Cap751.73M	Total Shares71.37M
T/O33.36M	T/O Rate4.55%	Tradable Shares40.42M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"MLTX","market":"US","secType":"STK","nameCN":"MoonLake Immunotherapeutics","latestPrice":18.6,"timestamp":1775678400000,"preClose":17.08,"halted":0,"volume":1839317,"hourTrading":{"tag":"盘后","latestPrice":18.5,"preClose":18.6,"latestTime":"19:56 EDT","volume":11939,"amount":221896.6722,"timestamp":1775692579722,"change":-0.1,"changeRate":-0.005376,"amplitude":0.005376},"delay":0,"changeRate":0.08899297423887607,"floatShares":40415700,"shares":71373579,"eps":-3.529999,"marketStatus":"Not Yet Opened","change":1.52,"latestTime":"04-08 16:00:00 EDT","open":17.38,"high":18.78,"low":17.1005,"amount":33361136.292845003,"amplitude":0.098331,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.529999,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1775721600000},"marketStatusCode":0,"adr":0,"listingDate":1603166400000,"exchange":"NASDAQ","adjPreClose":17.08,"preHourTrading":{"tag":"盘前","latestPrice":17.35,"preClose":17.08,"latestTime":"09:28 EDT","volume":2697,"amount":46973.330754,"timestamp":1775654880106,"change":0.27,"changeRate":0.015808,"amplitude":0.017553},"postHourTrading":{"tag":"盘后","latestPrice":18.5,"preClose":18.6,"latestTime":"19:56 EDT","volume":11939,"amount":221896.6722,"timestamp":1775692579722,"change":-0.1,"changeRate":-0.005376,"amplitude":0.005376},"volumeRatio":0.817306,"impliedVol":0.7673,"impliedVolPercentile":0.352},"requestUrl":"/m/hq/s/MLTX/wiki","defaultTab":"wiki","newsList":[{"id":"2624063973","title":"Major Insider Move at MoonLake Immunotherapeutics Shakes Up Investor Sentiment","url":"https://stock-news.laohu8.com/highlight/detail?id=2624063973","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624063973?lang=en_us&edition=fundamental","pubTime":"2026-04-03 10:01","pubTimestamp":1775181683,"startTime":"0","endTime":"0","summary":"New insider activity at MoonLake Immunotherapeutics ( ($MLTX) ) has taken place on April 2, 2026. Director Bvf Partners LP Il has executed a major ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/major-insider-move-at-moonlake-immunotherapeutics-shakes-up-investor-sentiment-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/major-insider-move-at-moonlake-immunotherapeutics-shakes-up-investor-sentiment-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MLTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624324687","title":"BVF Partners reports MoonLake Immunotherapeutics share sale worth $63.33 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2624324687","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624324687?lang=en_us&edition=fundamental","pubTime":"2026-04-03 04:49","pubTimestamp":1775162958,"startTime":"0","endTime":"0","summary":"BVF Partners reported sales of 3,749,999 MoonLake Immunotherapeutics Class A ordinary shares on March 31, 2026 at $16.79 per share.Holdings fell to 8,302,735 shares following reported transactions.Filing listed Mark N. Lampert as reporting person, shown as director, 10% owner.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moonlake Immunotherapeutics published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 02, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nNDL5b2QhS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"BVF Partners reports MoonLake Immunotherapeutics share sale worth $63.33 million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MLTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624392355","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Entrada Therapeutics Inc (TRDA), Apellis Pharmaceuticals (APLS) and MoonLake Immunotherapeutics (MLTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2624392355","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624392355?lang=en_us&edition=fundamental","pubTime":"2026-04-01 01:00","pubTimestamp":1774976423,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Entrada Therapeutics Inc (TRDA), Apellis Pharmaceu...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-entrada-therapeutics-inc-trda-apellis-pharmaceuticals-apls-and-moonlake-immunotherapeutics-mltx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-entrada-therapeutics-inc-trda-apellis-pharmaceuticals-apls-and-moonlake-immunotherapeutics-mltx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","BK4139","LU1093756168.USD","TRDA","BK4505","XBI","BK4137","BK4585","XLV","BK4581","APLS","MLTX","LU1093756325.SGD","BK4588","HCSG","LU0029874061.USD","LU0128526141.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623293344","title":"MoonLake Trial Data Continue to Support Efficacy of Sonelokimab to Treat Hidradenitis Suppurativa, Wedbush Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2623293344","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623293344?lang=en_us&edition=fundamental","pubTime":"2026-03-30 23:35","pubTimestamp":1774884909,"startTime":"0","endTime":"0","summary":"MoonLake Immunotherapeutics  reported 40-week data from its phase 3 VELA-1 and VELA-2 studies of sonelokimab to treat hidradenitis suppurativa that continue to support efficacy comparable to bimekizumab, Wedbush Securities said in a Monday note.Wedbush said updated results presented at the American Academy of Dermatology Annual Meeting showed continued efficacy improvement beyond week 16, with response levels broadly comparable to bimekizumab from UCB's phase 3 trials at 48 weeks.According to the report, the new VELA-2 data showed patients switching from placebo to sonelokimab improved rapidly within four weeks, helping explain earlier HiSCR75 variability and reinforcing the drug's underlying efficacy.The analysts said improvements in patient-reported outcomes and pain reduction aligned with lower lesion counts and limited placebo effects, supporting the therapeutic benefit of sonelokimab in hidradenitis suppurativa.The company plans to submit a biologics license application for sonelo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","MLTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623348342","title":"MoonLake Immunotherap Price Target Maintained With a $30.00/Share by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2623348342","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623348342?lang=en_us&edition=fundamental","pubTime":"2026-03-30 20:52","pubTimestamp":1774875120,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MLTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 30, 2026 08:52 ET (12:52 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MLTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623311622","title":"Analysts Offer Insights on Healthcare Companies: MoonLake Immunotherapeutics (MLTX), AbSci (ABSI) and MaxCyte (MXCT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2623311622","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623311622?lang=en_us&edition=fundamental","pubTime":"2026-03-30 19:02","pubTimestamp":1774868523,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on MoonLake Immunotherapeutics (MLTX), AbSci (ABSI) and...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-moonlake-immunotherapeutics-mltx-absci-absi-and-maxcyte-mxct-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-moonlake-immunotherapeutics-mltx-absci-absi-and-maxcyte-mxct-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","BK4139","BK4121","BK4588","MXCT","MLTX","BK4137","BK4539","XBI","LU0128526141.USD","BK4581","BK4585","XLV","HCSG","LU0029874061.USD","ABSI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623319140","title":"H.C. Wainwright Keeps Their Buy Rating on MoonLake Immunotherapeutics (MLTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2623319140","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623319140?lang=en_us&edition=fundamental","pubTime":"2026-03-30 18:36","pubTimestamp":1774866975,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on MoonLake Immunotherapeutics today and set a price target of $40.00. According to T...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-keeps-their-buy-rating-on-moonlake-immunotherapeutics-mltx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-keeps-their-buy-rating-on-moonlake-immunotherapeutics-mltx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MLTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623414351","title":"MoonLake Immunotherapeutics announces results from Phase 3 VELA-1, VELA-2 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2623414351","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623414351?lang=en_us&edition=fundamental","pubTime":"2026-03-29 22:35","pubTimestamp":1774794905,"startTime":"0","endTime":"0","summary":"MoonLake Immunotherapeutics (MLTX) announces long-term Week 40 results of the Phase 3 VELA-1 and VELA-2 clinical trials of its registrational globa...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/moonlake-immunotherapeutics-announces-results-from-phase-3-vela-1-vela-2-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/moonlake-immunotherapeutics-announces-results-from-phase-3-vela-1-vela-2-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","MLTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623338889","title":"MoonLake sonelokimab hits 62% HiSCR75 at Week 40 in Phase 3 HS trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2623338889","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623338889?lang=en_us&edition=fundamental","pubTime":"2026-03-29 03:00","pubTimestamp":1774724421,"startTime":"0","endTime":"0","summary":"MoonLake Immunotherapeutics released Week 40 data from Phase 3 VELA-1 and VELA-2 trials of sonelokimab in moderate-to-severe hidradenitis suppurativa, showing responses continued to strengthen over time.Pooled Week 40 results showed 62% of treated patients achieved HiSCR75, with up to 32% reaching HiSCR100.Lesion-level analysis showed up to 25% achieved inflammatory remission at Week 40, defined as complete clearance of abscesses, nodules, draining tunnels.Patient-reported outcomes improved, with up to 43% reporting at least 3-point improvement in worst skin pain score, while 65% posted at least 4-point improvement in DLQI.Data were scheduled for presentation later on March 28 at 2026 American Academy of Dermatology Annual Meeting; MoonLake also guided to 52-week VELA data in Q2 2026, with BLA submission for HS targeted in H2 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260328:nNDLbYhcY2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","LU2095319765.USD","NDAQ","SG9999014005.SGD","BK4588","SG9999014013.SGD","LU0314104364.USD","BK4112","SG9999014039.USD","MLTX","BK4585","BK4139","IE00B3QW5Z07.USD","IE00BN0W2T93.GBP","LU2210149790.SGD","IE00BN0W2W23.USD","IE00BN0W2V16.EUR","IE00BGHQF748.EUR","LU2210150020.SGD","IE00BKPKM429.USD","SG9999014021.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623380007","title":"MoonLake Announces Week 40 Results From Its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 Aad Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2623380007","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623380007?lang=en_us&edition=fundamental","pubTime":"2026-03-29 03:00","pubTimestamp":1774724401,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260328:nTUASKVPR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MLTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622860035","title":"MoonLake Immunotherapeutics management to meet with BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2622860035","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622860035?lang=en_us&edition=fundamental","pubTime":"2026-03-27 01:25","pubTimestamp":1774545933,"startTime":"0","endTime":"0","summary":"Group Dinner Meeting with Management.in New York on March 31 hosted by BTIG. Published first on TheFly – the ultimate source for real-time, market-...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/moonlake-immunotherapeutics-management-to-meet-with-btig-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/moonlake-immunotherapeutics-management-to-meet-with-btig-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","MLTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621792086","title":"MoonLake Immunotherapeutics Shares Rise After Wolfe Research Upgrade","url":"https://stock-news.laohu8.com/highlight/detail?id=2621792086","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621792086?lang=en_us&edition=fundamental","pubTime":"2026-03-24 03:01","pubTimestamp":1774292497,"startTime":"0","endTime":"0","summary":"MoonLake Immunotherapeutics  shares were up more than 3% in Monday trading after Wolfe Research upgraded the stock to outperform from underperform, and lifted its price target to $24 from $12.Trading volume stood at over 571,000 shares versus the daily average of 2 million.Price: 16.81, Change: +0.54, Percent Change: +3.32","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MLTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621707301","title":"MoonLake Immunotherap Raised to Outperform From Underperform by Wolfe Research","url":"https://stock-news.laohu8.com/highlight/detail?id=2621707301","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621707301?lang=en_us&edition=fundamental","pubTime":"2026-03-23 23:10","pubTimestamp":1774278600,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MLTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 23, 2026 11:10 ET (15:10 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MLTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621774320","title":"MoonLake upgraded to Outperform from Underperform at Wolfe Research","url":"https://stock-news.laohu8.com/highlight/detail?id=2621774320","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621774320?lang=en_us&edition=fundamental","pubTime":"2026-03-23 17:45","pubTimestamp":1774259129,"startTime":"0","endTime":"0","summary":"Wolfe Research double upgraded MoonLake Immunotherapeutics (MLTX) to Outperform from Underperform with a price target of $24, up from $12. The firm...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/moonlake-upgraded-to-outperform-from-underperform-at-wolfe-research-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/moonlake-upgraded-to-outperform-from-underperform-at-wolfe-research-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MLTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620738388","title":"Analysts Conflicted on These Healthcare Names: MoonLake Immunotherapeutics (MLTX), Solid Biosciences (SLDB) and Merck & Company (MRK)","url":"https://stock-news.laohu8.com/highlight/detail?id=2620738388","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620738388?lang=en_us&edition=fundamental","pubTime":"2026-03-20 19:10","pubTimestamp":1774005007,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on MoonLake Immunotherapeutics (MLTX), Solid Biosciences (SLDB) and ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-moonlake-immunotherapeutics-mltx-solid-biosciences-sldb-and-merck-company-mrk-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-moonlake-immunotherapeutics-mltx-solid-biosciences-sldb-and-merck-company-mrk-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0477156953.USD","IE00BSNM7G36.USD","LABU","LU1983299246.USD","LU1934455277.USD","LU0029874061.USD","LU0122379950.USD","LU0106261372.USD","LU0965509010.AUD","LU1917777945.USD","LU1430594728.SGD","LU1974910355.USD","IE0002141913.USD","BK4550","IE00BLSP4452.SGD","LU0320765489.SGD","IE00BLSP4239.USD","LU0265550946.USD","BK4137","SLDB","LU0965509283.SGD","LU1066051498.USD","SG9999015341.SGD","SG9999001176.USD","SG9999014542.SGD","LU0965509101.SGD","HCSG","IE00B4R5TH58.HKD","LU0985320562.USD","LU1162221912.USD","LU2361044949.HKD","LU0432979614.USD","LU0868494617.USD","LU2125154778.USD","MLTX","LU1116320737.USD","MRK","XLV","SG9999014575.USD","LU0648001328.SGD","SG9999013999.USD","LU1929549753.HKD","LU0266013472.USD","XBI","LU1934455863.HKD","LU0965508806.USD","LU1571399168.USD","LU2361045086.USD","LU0211331839.USD","LU1989772923.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620738974","title":"Assessing MoonLake Immunotherapeutics (MLTX) Valuation After Cormorant’s Large Share Purchase","url":"https://stock-news.laohu8.com/highlight/detail?id=2620738974","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620738974?lang=en_us&edition=fundamental","pubTime":"2026-03-20 19:07","pubTimestamp":1774004859,"startTime":"0","endTime":"0","summary":"Institutional buying sparks new attention on MoonLake Immunotherapeutics\nCormorant Asset Management’s recent SEC filing, showing a purchase of over 2.3 million MoonLake Immunotherapeutics (NasdaqCM:MLTX) shares for an estimated US$27.86 million, has put the clinical stage biotech back on investor watchlists.\nSee our latest analysis for MoonLake Immunotherapeutics.\nMoonLake’s recent 2.8% 1 day share price return to US$16.68 comes after a sharp sell off last year, with a 1 year total...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mltx/moonlake-immunotherapeutics/news/assessing-moonlake-immunotherapeutics-mltx-valuation-after-c","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mltx/moonlake-immunotherapeutics/news/assessing-moonlake-immunotherapeutics-mltx-valuation-after-c","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","MLTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620220020","title":"MoonLake Immunotherap Raised to Buy From Neutral by Rothschild & Co","url":"https://stock-news.laohu8.com/highlight/detail?id=2620220020","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620220020?lang=en_us&edition=fundamental","pubTime":"2026-03-20 01:35","pubTimestamp":1773941700,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MLTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 19, 2026 13:35 ET (17:35 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MLTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620243369","title":"MoonLake upgraded to Buy from Neutral at Rothschild & Co Redburn","url":"https://stock-news.laohu8.com/highlight/detail?id=2620243369","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620243369?lang=en_us&edition=fundamental","pubTime":"2026-03-19 16:50","pubTimestamp":1773910228,"startTime":"0","endTime":"0","summary":"Rothschild & Co Redburn analyst Qize Ding upgraded MoonLake Immunotherapeutics (MLTX) to Buy from Neutral with a price target of $40, up from $12. ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/moonlake-upgraded-to-buy-from-neutral-at-rothschild-co-redburn-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/moonlake-upgraded-to-buy-from-neutral-at-rothschild-co-redburn-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","MLTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619016301","title":"MoonLake Immunotherapeutics: Sonelokimab’s Differentiated IL‑17A/F Profile and Multibillion-Dollar Potential Underpin Buy Rating Despite HS Trial Concerns","url":"https://stock-news.laohu8.com/highlight/detail?id=2619016301","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619016301?lang=en_us&edition=fundamental","pubTime":"2026-03-13 14:05","pubTimestamp":1773381924,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Phil Nadeau has maintained their bullish stance on MLTX stock, giving a Buy rating on March 11. Phil Nadeau has given his Buy rati...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/moonlake-immunotherapeutics-sonelokimabs-differentiated-il‑17a-f-profile-and-multibillion-dollar-potential-underpin-buy-rating-despite-hs-trial-concerns-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/moonlake-immunotherapeutics-sonelokimabs-differentiated-il‑17a-f-profile-and-multibillion-dollar-potential-underpin-buy-rating-despite-hs-trial-concerns-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MLTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618941636","title":"MoonLake Immunotherap Is Maintained at Buy by Clear Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2618941636","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618941636?lang=en_us&edition=fundamental","pubTime":"2026-03-11 19:25","pubTimestamp":1773228300,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MLTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 11, 2026 07:25 ET (11:25 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MLTX"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.moonlaketx.com","stockEarnings":[{"period":"1week","weight":-0.0837},{"period":"1month","weight":-0.059},{"period":"3month","weight":0.5128},{"period":"6month","weight":0.8209},{"period":"1year","weight":-0.5089},{"period":"ytd","weight":0.2959}],"compareEarnings":[{"period":"1week","weight":0.0137},{"period":"1month","weight":-0.0196},{"period":"3month","weight":-0.044},{"period":"6month","weight":-0.0178},{"period":"1year","weight":0.307},{"period":"ytd","weight":-0.0333}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or axial spondyloarthritis. MoonLake Immunotherapeutics was incorporated in 2021 and is headquartered in Zug, Switzerland.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":0.01118},{"month":2,"riseRate":0.5,"avgChangeRate":0.083781},{"month":3,"riseRate":0.666667,"avgChangeRate":0.033144},{"month":4,"riseRate":0.166667,"avgChangeRate":-0.107778},{"month":5,"riseRate":0.4,"avgChangeRate":0.086858},{"month":6,"riseRate":0.8,"avgChangeRate":0.175967},{"month":7,"riseRate":0.6,"avgChangeRate":0.073307},{"month":8,"riseRate":0.6,"avgChangeRate":0.090179},{"month":9,"riseRate":0.4,"avgChangeRate":-0.166769},{"month":10,"riseRate":0.6,"avgChangeRate":0.061028},{"month":11,"riseRate":0.666667,"avgChangeRate":0.098535},{"month":12,"riseRate":0.5,"avgChangeRate":0.079459}],"exchange":"NASDAQ","name":"MoonLake Immunotherapeutics","nameEN":"MoonLake Immunotherapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"MoonLake Immunotherapeutics(MLTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest MoonLake Immunotherapeutics(MLTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"MoonLake Immunotherapeutics,MLTX,MoonLake Immunotherapeutics股票,MoonLake Immunotherapeutics股票老虎,MoonLake Immunotherapeutics股票老虎国际,MoonLake Immunotherapeutics行情,MoonLake Immunotherapeutics股票行情,MoonLake Immunotherapeutics股价,MoonLake Immunotherapeutics股市,MoonLake Immunotherapeutics股票价格,MoonLake Immunotherapeutics股票交易,MoonLake Immunotherapeutics股票购买,MoonLake Immunotherapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"MoonLake Immunotherapeutics(MLTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest MoonLake Immunotherapeutics(MLTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}